Hook / Thesis
Bausch + Lomb (BLCO) is a market leader in eye health that is priced more like a stressed balance sheet than a stable, mid-single-digit growth healthcare company. Headlines about a past enVista intraocular lens recall and a securities probe have kept a shadow over the stock, but the business continues to generate revenue and free cash flow: the company reported roughly $5.1 billion in annual revenue with ~6% year-over-year growth, and produced $137 million in free cash flow most recently.
At the current price (~$17.20), the market cap sits around $6.14 billion$10.98 billion. That gap tells the story: investors are assigning a hefty premium to liability, litigation and balance-sheet risk while underweighting the three operating engines - Vision Care/Consumer Health, Ophthalmic Pharmaceuticals and Surgical - that drive growth and margin recovery.
Why the market should care
Bausch + Lomb makes products that are relatively recession-resilient (contact lenses, post-operative pharma, cataract equipment and IOLs). Market tailwinds are favorable: the global ophthalmology devices market is forecast to grow strongly, and the ophthalmic drugs market is expanding with durable drivers like ageing populations and innovation in long-acting therapeutics.
Critically, the company's fundamentals show operating recovery potential. Revenue is growing, adjusted EBITDA took a hit in 2025 because of recall-related headwinds (management cited roughly $55 million-$65 million of adjusted EBITDA pressure), but that was an identifiable, one-time-like shock. With product launches in pharmaceuticals (for example, MIEBO) and continued traction in contact lenses and consumer eye-health channels, the operating business has a clear runway to re-earn a higher multiple if event risk fades.
Supporting numbers
- Current price: $17.20; 52-week range: $13.77 - $18.92.
- Market cap: $6.14B; enterprise value: $10.98B.
- Revenue: ~$5.1B with ~6% YoY growth reported.
- Free cash flow: $137M; price-to-free-cash-flow is elevated (reflecting a discount in equity value).
- Profitability: trailing EPS is negative at about -$0.48, P/E is not meaningful; other multiples: P/S ~1.17, EV/EBITDA ~12.6x.
- Balance sheet / liquidity: debt-to-equity about 0.8, current ratio ~1.55, quick ratio ~1.02. These are not liquidation-level numbers, but the market is clearly attaching a risk premium.
- Technicals: 50-day SMA ~$16.30, 20-day SMA ~$16.78, MACD in bullish momentum, RSI ~59 - price has room to run and is above its shorter-term moving averages.
- Short interest: recent settlement (07/31/2026) shows ~3.03M shares short, days-to-cover ~5.9. Short volumes have been meaningful in recent sessions, which can amplify moves on positive catalysts.
Valuation framing
At today's equity valuation (~$6.14B market cap), the company trades at a modest P/S (~1.17). EV/EBITDA of ~12.6x is reasonable for a stable medical-specialties business with mid-single-digit revenue growth, but the equity itself is depressed relative to enterprise value because investors are baking in liability risk and a higher cost of equity.
Think of the current market price as a two-piece equation: one piece is the operating business that generates $5.1B of revenue, consistent cash flow and structural demand for eye care; the other piece is event risk - recall, litigation and periodic headline volatility - that can be resolved over time or at least quantified. If operating momentum holds and legal/recall-related costs remain contained, the equity should rerate toward multiples more typical for peers in eye-care devices and pharmaceuticals, narrowing the gap between EV and market cap.
Catalysts (what will drive this trade)
- Operational cadence: a clean quarter showing sequential margin recovery as recall-related costs fade and surgical/pharma mix improves.
- Product momentum: adoption of new ophthalmic pharmaceuticals (MIEBO) and continued growth in contact lens/consumer health categories.
- Legal clarity: resolution or narrowing of the securities probe and recall exposure, which would remove a headline overhang.
- Investor repositioning: large shareholders or new buyers (institutional interest) increasing exposure; recent activity by a major investor signals conviction and could attract momentum flows.
Trade plan (actionable entry, stop, target and horizon)
| Entry | Target | Stop | Direction | Horizon |
|---|---|---|---|---|
| $17.20 | $21.00 | $15.00 | Long | Mid term (45 trading days) |
Rationale: enter at the current price ($17.20) and target a ~22% upside to $21.00 over a mid-term window of 45 trading days. This horizon gives time for quarterly results or operational updates to filter through and for sentiment to shift as recall-related costs roll out of the headline cycle. The stop at $15.00 protects against a deeper re-rating should additional negative developments (new recall news, unexpectedly large legal reserve) emerge.
Position sizing & risk framing
This is a medium-risk trade. The company is operating, generating cash, and sits in a durable market, but headline and legal tail risks can produce sharp downside. Size positions so that a drop from $17.20 to $15.00 is within your predefined loss tolerance (for many traders that would be 1-2% of portfolio risk per trade). Consider using staggered entries and partial profit-taking into the target, especially if you see several catalysts resolve earlier than expected.
Risks and counterarguments
- Legal and recall upside risk: The company has been the subject of a securities investigation and a voluntary recall tied to enVista IOLs. Additional findings or larger-than-expected reserves could materially depress the equity.
- Persistent margin pressure: If the recall or supply-chain issues create ongoing revenue mix shifts or higher costs beyond the previously disclosed ~$55M-$65M EBITDA impact, margin recovery could be slower than expected.
- Liquidity / capital allocation risk: While current ratios (~1.55) and debt-to-equity (~0.8) are manageable, a larger-than-expected cash outflow for legal settlements would pressure flexibility and could force dilutive actions or asset sales.
- Competition and innovation risk: The ophthalmic devices and drugs markets are competitive; rapid innovation or superior competitor launches could blunt growth and pricing power.
- Counterargument: The market may be right to discount the equity. On a price-to-free-cash-flow basis the company looks expensive relative to near-term cash generation (price-to-free-cash-flow elevated), which suggests the market is correctly pricing unresolved balance-sheet and event risk. If additional negative information emerges, the current valuation gap to enterprise value could widen and shares could trade materially lower.
What would change my mind
I will trim or exit the position if any of the following occur: (1) management discloses materially higher-than-anticipated recall-related reserves or ongoing monthly EBITDA drag; (2) new regulatory findings materially expand the scope of the recall or suggest product-level defects; (3) cash flow turns negative in a sustained manner or the company announces dilutive capital raises to cover liabilities. Conversely, I would add to the position if the company delivers a clean quarter with visible margin improvement, provides legal clarity that substantially reduces headline risk, or if institutional buyers increase stakes marking a structural rerating.
Bottom line
Bausch + Lomb is a classic asymmetric trade where headline-driven fear has compressed the equity while the operating engine still produces revenue growth and free cash flow. With an entry at $17.20, a disciplined $15.00 stop and a $21.00 target over a mid-term window (45 trading days), this trade offers a reasonable risk-reward: the upside is driven by operational recovery and removal of headline overhang, while the downside is contained by a clear stop and manageable balance-sheet metrics.
Key monitorables going forward
- Quarterly results for organic growth and margin trends.
- Any material updates on recall or securities probe resolution.
- Free cash flow trajectory and changes to capital allocation (buybacks, dividends, M&A).
- Short interest and short-volume spikes that could accelerate moves in either direction.
Trade idea summary: Long BLCO at $17.20, target $21.00, stop $15.00, mid-term (45 trading days). This is a medium-risk, catalyst-driven swing trade that relies on fading headline risk and visible operating recovery.